PH12018502155A1 - Pharmaceutical composition comprising a beta blocker, a converting enzyme inhibitor and an antihypertensive or an nsaid - Google Patents

Pharmaceutical composition comprising a beta blocker, a converting enzyme inhibitor and an antihypertensive or an nsaid

Info

Publication number
PH12018502155A1
PH12018502155A1 PH12018502155A PH12018502155A PH12018502155A1 PH 12018502155 A1 PH12018502155 A1 PH 12018502155A1 PH 12018502155 A PH12018502155 A PH 12018502155A PH 12018502155 A PH12018502155 A PH 12018502155A PH 12018502155 A1 PH12018502155 A1 PH 12018502155A1
Authority
PH
Philippines
Prior art keywords
antihypertensive
nsaid
beta blocker
pharmaceutical composition
converting enzyme
Prior art date
Application number
PH12018502155A
Other versions
PH12018502155B1 (en
Inventor
Gilles Fonknechten
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of PH12018502155A1 publication Critical patent/PH12018502155A1/en
Publication of PH12018502155B1 publication Critical patent/PH12018502155B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention relates to fixed-combination pharmaceutical compositions comprising a beta blocker (bisoprolol), an antihypertensive agent (perindopril) and a 3rd therapeutic agent. The invention further relates to the use of said composition for the treatment and prevention of cardiovascular diseases, more particularly hypertension and stable coronary disease.
PH1/2018/502155A 2016-04-20 2016-04-19 Pharmaceutical composition comprising a beta blocker, a converting enzyme inhibitor and an antihypertensive or an nsaid PH12018502155B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1653502A FR3050380B1 (en) 2016-04-20 2016-04-20 PHARMACEUTICAL COMPOSITION COMPRISING A BETA-BLOCKER, A CONVERSION ENZYME INHIBITOR AND AN ANTIHYPERTENSOR OR NSAID.
PCT/FR2017/050929 WO2017182754A1 (en) 2016-04-20 2017-04-19 Pharmaceutical composition comprising a beta blocker, a converting enzyme inhibitor and an antihypertensive or an nsaid

Publications (2)

Publication Number Publication Date
PH12018502155A1 true PH12018502155A1 (en) 2019-07-15
PH12018502155B1 PH12018502155B1 (en) 2024-03-27

Family

ID=56943614

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2018/502155A PH12018502155B1 (en) 2016-04-20 2016-04-19 Pharmaceutical composition comprising a beta blocker, a converting enzyme inhibitor and an antihypertensive or an nsaid

Country Status (15)

Country Link
EP (1) EP3445342A1 (en)
KR (1) KR102267965B1 (en)
CN (1) CN109069438A (en)
BR (1) BR112018070968A2 (en)
EA (1) EA201892354A1 (en)
FR (1) FR3050380B1 (en)
GE (2) GEP20217310B (en)
MA (1) MA44728A (en)
MX (1) MX389586B (en)
PH (1) PH12018502155B1 (en)
RU (1) RU2756320C2 (en)
SG (2) SG11201808848SA (en)
TN (1) TN2018000344A1 (en)
UA (1) UA125511C2 (en)
WO (1) WO2017182754A1 (en)

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2645710C2 (en) 1976-10-09 1985-06-27 Merck Patent Gmbh, 6100 Darmstadt Phenoxy-aminopropanols, process for their manufacture and pharmaceutical preparation
FR2503155A2 (en) 1980-10-02 1982-10-08 Science Union & Cie NOVEL SUBSTITUTED IMINO DIACIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS AN ENZYME INHIBITOR
FR2620709B1 (en) 1987-09-17 1990-09-07 Adir PROCESS FOR THE INDUSTRIAL SYNTHESIS OF PERINDOPRIL AND ITS MAIN INTERMEDIATE SYNTHESIS
FR2807431B1 (en) 2000-04-06 2002-07-19 Adir NOVEL PROCESS FOR THE SYNTHESIS OF PERINDOPRIL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS
GB2361185A (en) * 2000-04-10 2001-10-17 Nicholas J Wald Pharmaceutical formulation for the prevention of cardiovascular disease
AR036187A1 (en) 2001-07-24 2004-08-18 Adir A PROCESS FOR THE PREPARATION OF PERINDOPRIL, ANALOG COMPOUNDS AND ITS SALTS, INTERMEDIARY COMPOUND 2,5-DIOXO-OXAZOLIDINE AND PROCESS TO PREPARE A INTERMEDIARY
FR2827860B1 (en) 2001-07-24 2004-12-10 Servier Lab NOVEL PROCESS FOR SYNTHESIS OF ACID DERIVATIVES (2S, 3AS, 7AS) -1 - [(S) -ALANYL] -OCTAHYDRO-1H-INDOLE-2-CARBOXYLINE AND APPLICATION TO THE SYNTHESIS OF PERINDOPRIL
ATE365714T1 (en) 2002-01-30 2007-07-15 Servier Lab METHOD FOR PRODUCING HIGH PURITY PERINDOPRIL AND INTERMEDIATE COMPOUNDS USEFUL IN SYNTHESIS
FR2838648B1 (en) 2002-04-18 2004-05-21 Servier Lab NEW PERINDOPRIL SALT AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING IT
ATE395913T1 (en) 2003-02-28 2008-06-15 Servier S A Lab METHOD FOR PRODUCING PERINDOPRIL
DE60301930T2 (en) 2003-02-28 2006-07-27 Les Laboratoires Servier Process for the synthesis of perindopril and its pharmaceutically acceptable salts
PT1321471E (en) 2003-03-12 2005-07-29 Servier Lab NEW SYNTHESIS OF PERINDOPRIL AND ITS ACEITABLE SALTS UNDER THE PHARMACEUTICAL VISION
SI1367061T1 (en) 2003-06-30 2006-04-30 Servier Lab Method for synthesis of perindopril and its pharmaceutically acceptable salts
SI1362864T1 (en) 2003-06-30 2007-08-31 Servier Lab Method for synthesis of perindopril and its pharmaceutically acceptable salts
EP1648422A4 (en) * 2003-07-28 2007-09-19 Reddys Lab Inc Dr Treatment and preventi0n of cardiovascular events
DK1367062T3 (en) 2003-07-31 2007-01-02 Servier Lab New method for synthesis of perindopril and pharmaceutically acceptable salts thereof
ES2271498T3 (en) 2003-07-31 2007-04-16 Les Laboratoires Servier NEW SYNTHESIS PROCEDURE OF PERINDOPRIL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS.
EP1380591B1 (en) 2003-08-29 2005-11-16 Les Laboratoires Servier Method for synthesis of perindopril and its pharmaceutically acceptable salts
ES2250853T3 (en) 2003-08-29 2006-04-16 Les Laboratoires Servier PROCEDURE FOR THE SYNTHESIS OF PERINDOPRIL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS.
DE60308102T2 (en) 2003-08-29 2007-06-21 Les Laboratoires Servier Process for the synthesis of perindopril and its pharmaceutically acceptable salts
DE60311942T2 (en) 2003-11-19 2007-12-06 Les Laboratoires Servier Process for the synthesis of perindopril and its pharmaceutically acceptable salts
EP1422236B1 (en) 2003-11-19 2007-02-14 Les Laboratoires Servier Method for synthesis of perindopril and its pharmaceutically acceptable salts
SI1420029T1 (en) 2003-12-10 2008-08-31 Servier Lab Method for synthesis of perindopril and its pharmaceutically acceptable salts
SI21800A (en) 2004-05-14 2005-12-31 Krka, Tovarna Zdravil, D.D., Novo Mesto New procedure of synthesis of perindopril
US20070116756A1 (en) * 2005-11-23 2007-05-24 Dr. Reddy's Laboratories Limited Stable pharmaceutical compositions
FR2894825B1 (en) 2005-12-21 2010-12-03 Servier Lab NOVEL ASSOCIATION OF SINUSAL IF CURRENT INHIBITOR AND CONVERSION ENZYME INHIBITOR AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
FR2897866B1 (en) 2006-02-28 2008-04-18 Servier Lab ALPHA CRYSTALLINE FORM OF PERINOPRIL ARGININE SALT, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
FR2897865B1 (en) 2006-02-28 2008-04-18 Servier Lab BETA CRYSTALLINE SHAPE OF PERINOPRIL ARGININE SALT, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
CN101024082A (en) * 2007-04-06 2007-08-29 张士东 Compounded medicine for wholely preventing and treating cardio-cerebral blood vessel diseases and use thereof
AU2009263737B2 (en) 2008-06-24 2013-10-24 Tianish Laboratories Private Limited Novel polymorphic forms of Perindopril (L)-Arginine and process for the preparation thereof
HU230877B1 (en) 2008-09-30 2018-11-29 EGIS Gyógyszergyár NyR Stable combination medicine
US9789187B2 (en) * 2009-02-11 2017-10-17 Cadila Pharmaceuticals Limited Stable pharmaceutical composition for atherosclerosis
EP2424509A4 (en) * 2009-04-30 2012-11-07 Reddys Lab Ltd Dr Fixed dose drug combination formulations
FR2961105B1 (en) 2010-06-15 2013-02-08 Servier Lab USE OF THE ASSOCIATION OF A SINUSAL IF CURRENT INHIBITOR AND AN INHIBITOR OF THE ANGIOTENSIN CONVERSION ENZYME FOR THE TREATMENT OF CARDIAC INSUFFICIENCY
FR2985511B1 (en) 2012-01-05 2014-01-03 Servier Lab CRYSTALLINE DELTA FORM OF PERINOPRIL ARGININE SALT, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME

Also Published As

Publication number Publication date
SG11201808848SA (en) 2018-11-29
RU2018140193A3 (en) 2020-06-03
PH12018502155B1 (en) 2024-03-27
FR3050380B1 (en) 2020-07-10
FR3050380A1 (en) 2017-10-27
MA44728A (en) 2019-02-27
KR102267965B1 (en) 2021-06-21
MX389586B (en) 2025-03-20
WO2017182754A1 (en) 2017-10-26
GEAP202114923A (en) 2021-07-12
RU2018140193A (en) 2020-05-20
KR20180132911A (en) 2018-12-12
UA125511C2 (en) 2022-04-13
TN2018000344A1 (en) 2020-06-15
EA201892354A1 (en) 2019-04-30
BR112018070968A2 (en) 2019-01-29
RU2756320C2 (en) 2021-09-29
CN109069438A (en) 2018-12-21
EP3445342A1 (en) 2019-02-27
SG10202009894PA (en) 2020-11-27
GEP20217310B (en) 2021-11-10

Similar Documents

Publication Publication Date Title
BR112016020199A8 (en) human plasma kallikrein inhibitor compound, pharmaceutical composition comprising said compound, kit and its use
PH12019502201A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
ZA202204941B (en) Cd73 inhibitors
GEP20156239B (en) Benzofuranyl derivatives used as glucokinase inhibitors
PH12019502577A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
PH12019502095A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
PH12019502559A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
PH12019502782A1 (en) Fixed dose formulations
EA202191955A1 (en) MODIFIED RELEASE TABLET FORMULATIONS CONTAINING PHOSPHODIESTERASE INHIBITORS
JOP20200100A1 (en) Pyrazolo-pyrrolo-pyrimidine-diene derivatives are new as P2X3 inhibitors
MX2021003643A (en) Terpinoid derivatives and uses thereof.
MX2019006863A (en) Heparanase inhibitors and use thereof.
MX2023005913A (en) Benzenesulfonamide derivatives and uses thereof.
MX393915B (en) NEW ORAL FORMULATIONS OF BELINOSTAT.
MX2019013970A (en) Delayed sustained release pharmaceutical compositions.
PH12018502155A1 (en) Pharmaceutical composition comprising a beta blocker, a converting enzyme inhibitor and an antihypertensive or an nsaid
PH12018500370A1 (en) Pharmaceutical composition comprising an hmg-coa reductase inhibitor and an ace inhibitor
PH12017500786A1 (en) Pharmaceutical composition comprising a beta blocker and an angiotensin converting enzyme inhibitor
MX2021007967A (en) Leukotriene synthesis inhibitors.
MX2021000475A (en) Isoxazole as fxr receptor agonists.
MY206575A (en) Isochromene derivatives as phosphoinositide 3-kinases inhibitors
MY204443A (en) Pyridopyrimidinone derivatives for use as axl inhibitors
AU2019904685A0 (en) Compositions and methods for prevention and treatment of cardiovascular disease.
AU2019904682A0 (en) Compositions and methods for prevention and treatment of cardiovascular disease.
MX2019014773A (en) Ccl2 inhibitors.